Binding of RAGE and RIPK1 induces cognitive deficits in chronic hyperglycemia-derived neuroinflammation.
Level 5 - mechanism / opinion, no new human data
Preclinical animal (db/db mouse) and in vitro molecular study without human data.
PubMed 37665158 · doi:10.1111/cns.14449
What was done
Using db/db mice as a model of type 2 diabetes, researchers investigated the interaction between the receptor for advanced glycation end products (RAGE) and receptor-interacting serine/threonine protein kinase 1 (RIPK1) in hippocampal microglia. Techniques included GST pull-down assays, AutoDock Vina docking simulations, Western blotting, co-immunoprecipitation, and immunofluorescence. Cognitive performance was assessed using the Morris water maze, novel object recognition, and fear-conditioning tests before and after mutating RAGE amino acids 362-367.
What was found
The abstract reports no numerical values, effect sizes, or sample sizes. Directionally, RAGE directly bound to RIPK1 via amino acids 362-367, upregulating RIPK1 phosphorylation and activating the microglial NLRP3 inflammasome, leading to cognitive impairments in db/db mice. Mutating RAGE amino acids 362-367 reversed hippocampal neuroinflammation and improved cognitive performance.
Why it matters
The study identifies a specific structural binding site (amino acids 362-367) linking RAGE to RIPK1 and microglial inflammasome activation, suggesting a potential molecular target for addressing diabetes-induced cognitive deficits.
Limits
Findings are derived entirely from rodent models and in vitro assays; applicability to human diabetic encephalopathy is unknown. The abstract does not provide sample sizes, effect magnitudes, variance estimates, or statistical significance metrics. Non-microglial cell contributions and potential off-target effects of the RAGE mutation were not reported.
Cited by
- supports RAGE receptors on microglial cells respond to advanced glycation end products resulting from chronically elevated blood sugar.